Evidence map›Paper›PMID 16517585›Full record

ReviewThorax2006

COPD exacerbations . 2: aetiology.

E Sapey, R A Stockley

3 registry-linked trialsAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Thorax, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 188 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
188citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02386735 naterminatednot on this mapstarted 2015, after this paper: background citation

Reduction of Corticosteroid Use in Outpatient Treatment of Exacerbated COPD - a Randomized, Double-blind, Non-inferiority Study (The "RECUT"-Trial)

TypeinterventionalSponsorProf. Dr. Jörg LeuppiRan2015 to 2024Enrolled133ConditionsPulmonary Disease, Chronic Obstructive, Adverse Effect of Glucocorticoids and Synthetic Analogues, Disease ExacerbationArmsPlacebo, Prednisone
NCT05286918 nanot yet recruitingnot on this mapstarted 2022, after this paper: background citation

Antibiotic Stewardship Through CRP-guided Antibiotic Treatment for Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

TypeinterventionalSponsorThe University of Hong KongRan2022 to 2026Enrolled1,184ConditionsAcute Exacerbation of COPD, Lung Diseases, Lung Diseases, Obstructive, Pulmonary Disease, Chronic ObstructiveArmsThe intervention (CRP-guided) group
NCT06314035 naunknown statusnot on this mapstarted 2024, after this paper: background citation

"Effects of a Decision Support Intervention on End-of-life Care Planning in Chinese Older Adults With Advanced Disease and Their Family Members: A Feasibility Trial"

TypeinterventionalSponsorNational Taipei University of Nursing and Health SciencesRan2024 to 2025Enrolled60ConditionsChronic Obstructive Pulmonary DiseaseArmsCOPD Patient Decision Aid, General Health Coaching Intervention
3 · Its place in the literature

Who cites it

188 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Vitamin D for the management of chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2024
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Association of Short-Term Pollen Exposure With Lung Function in COPD Patients.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Afebrile Presentation in COPD Patients with Influenza A: A Risk Factor for Prolonged Viral Shedding.International journal of chronic obstructive pulmonary disease · 2026
    Article

128 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

E SapeyLung Investigation Unit, Queen Elizabeth Hospital, Birmingham B15 2TH, UK.
R A Stockley

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exacerbations of COPD are thought to be caused by complex interactions between the host, bacteria, viruses, and environmental pollution. These factors increase the inflammatory burden in the lower airways, overwhelming the protective anti-inflammatory defences leading to tissue damage. Frequent exacerbations are associated with increased morbidity and mortality, a faster decline in lung function, and poorer health status, so prevention or optimal treatment of exacerbations is a global priority. In order to evolve new treatment strategies there has been great interest in the aetiology and pathophysiology of exacerbations, but progress has been hindered by the heterogeneous nature of these episodes, vague definitions of an exacerbation, and poor stratification of known confounding factors when interpreting results. We review how an exacerbation should be defined, its inflammatory basis, and the importance of exacerbations on disease progression. Important aetiologies, with their potential underlying mechanisms, are discussed and the significance of each aetiology is considered.

Indexed as

Bacterial InfectionsBiomarkersBronchitisCytokinesEnvironmental PollutionHumansProteinsPulmonary Disease, Chronic ObstructiveSputumVirus DiseasesBiomarkersCytokinesProteins

Identifiers

PMID16517585
PMCPMC2080749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.